Horizon Therapeutics Public Limited Company – NASDAQ:HZNP

Add to watchlist

Market closed

Open in 1 day

+0.68%

month

+14.66%

quarter

+73.45%

year

Market Cap	N/A
Enterprise value	25.08B

P/E	49.34
EV/Sales	6.91
EV/EBITDA	25.06
Price/Sales	6.85
Price/Book	4.90
PEG ratio	-12.99
EPS	1.92

Revenue	3.64B
EBITDA	957.02M
Income	438.00M
Revenue Q/Q	7.82%
Revenue Y/Y	-4.42%

Profit margin	14.37%
Oper. margin	19.59%
Gross margin	74.64%
EBIT margin	19.59%
EBITDA margin	26.26%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Profit margin
Sep 2022	925.35M	135.83M	14.68%
Dec 2022	942.02M	120.40M	12.78%
Mar 2023	832.05M	54.68M	6.57%
Jun 2023	944.95M	127.07M	13.45%

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Earnings per share (EPS)
2023-03-01	1.09	1.21
2023-05-03	1.17	0.83
2023-08-08	1.12	1.2
2023-11-01	1.22	1.25

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Debt to assets
Sep 2022	9027862000	3.99B	44.24%
Dec 2022	9114616000	4.04B	44.35%
Mar 2023	8993450000	3.89B	43.34%
Jun 2023	9298741000	3.98B	42.89%

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Cash Flow
Sep 2022	366.46M	-32.02M	-94.37M
Dec 2022	426.39M	-49.07M	-160.96M
Mar 2023	86.32M	-41.75M	-88.12M
Jun 2023	161.46M	-20.02M	9.03M

Horizon Therapeutics Public Limited Company alternative data

Horizon Therapeutics Public Limited Company
Employees

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Employee count
Aug 2023	2,145
Sep 2023	2,190
Oct 2023	2,190
Nov 2023	2,190
Dec 2023	2,190
Jan 2024	2,190
Feb 2024	2,190
Mar 2024	2,190
Apr 2024	2,190
May 2024	2,190
Jun 2024	2,190
Jul 2024	2,190

Horizon Therapeutics Public Limited Company
Hedge Funds Holdings Q2 2022

85.87% -0.73%

of HZNP is owned by hedge funds

589 -12

hedge funds hold HZNP stock

202.60M -1.48M

shares is hold by hedge funds

HZNP hedge funds holdings changes

Horizon Therapeutics Public Limited Company
Insider Trading

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP): Insider trades (number of shares)
Period	Buy	Sel
Feb 2022	0	101313
Mar 2022	0	174933
Apr 2022	0	477366
May 2022	0	100000
Jun 2022	0	25762
Jul 2022	0	10939
Aug 2022	745	0
Dec 2022	0	58521
Jan 2023	0	75200

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	28 Apr 2023	MAHONY SUSAN director director	Restricted Stock Units	3,913	N/A	N/A
Option	28 Apr 2023	DANIEL WILLIAM F director director	Ordinary Shares	3,913	N/A	N/A
Option	28 Apr 2023	DANIEL WILLIAM F director director	Restricted Stock Units	3,913	N/A	N/A
Option	28 Apr 2023	HIMAWAN JEFF director director	Ordinary Shares	3,913	N/A	N/A
Option	28 Apr 2023	HIMAWAN JEFF director director	Restricted Stock Units	3,913	N/A	N/A
Option	28 Apr 2023	GREY MICHAEL G director	Ordinary Shares	3,913	N/A	N/A
Option	28 Apr 2023	GREY MICHAEL G director	Restricted Stock Units	3,913	N/A	N/A
Option	28 Apr 2023	SHANNON JAMES SAMUEL director director	Ordinary Shares	3,913	N/A	N/A
Option	28 Apr 2023	SHANNON JAMES SAMUEL director director	Restricted Stock Units	3,913	N/A	N/A
Option	28 Apr 2023	MAHONY SUSAN director director	Ordinary Shares	3,913	N/A	N/A

HZNP insider trading transactions

Horizon Therapeutics Public Limited Company
Earnings Call Transcripts

Quarter	Transcript
Q3 2022 2 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 3 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 4 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 1 Mar 2022	Q4 2021 Earnings Call Transcript

HZNP earnings call transcripts

Horizon Therapeutics Public Limited Company
Executives

Insider	Age	Compensation
Mr. Timothy P. Walbert (1967) Chairman, Pres & Chief Executive Officer	58	$5,480,000
Mr. Paul W. Hoelscher (1965) Executive Vice President & Chief Financial Officer	60	$1,880,000
Mr. Andy Pasternak (1971) Executive Vice President & Chief Strategy Officer	54	$1,790,000
Mr. Barry J. Moze (1954) Executive Vice President & Chief Admin. Officer	71	$1,710,000
Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D. (1955) Executive Vice President & Chief Medical Officer	70	$1,550,000

Horizon Therapeutics Public Limited Company
Latest News

Tuesday, 6 February 2024
16:05	Amgen quarterly profit rises 15% as Horizon deal boosts results	Reuters
Thursday, 21 December 2023
13:05	5 Biotech Acquisition Targets To Accumulate In 2024	Seeking Alpha
Friday, 13 October 2023
14:00	Amgen: Horizon's Pipeline May Be Too Expensive	Seeking Alpha
Friday, 6 October 2023
09:18	Amgen completes $27.8 bln Horizon deal	Reuters
Wednesday, 6 September 2023
10:56	3 Growth Stocks to Buy in September	MarketBeat
Tuesday, 5 September 2023
12:56	The FTC cleared Amgen's $27.8 billion Horizon buyout — here's what it means for other massive pharma deals	CNBC
09:05	Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement	Business Wire
Friday, 1 September 2023
14:11	Amgen gets green light from FTC for $27.8B Horizon Therapeutics deal	Fox Business
11:59	FTC clears Amgen's $28 billion acquisition of Horizon Therapeutics	Invezz
10:53	Amgen's $27.8 Billion Purchase Of Horizon Therapeutics On After FTC Settlement	Forbes
10:11	Amgen, Horizon Therapeutics Stocks Rise After FTC Settlement Over $27.8 Billion Merger	Barrons
09:33	FTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics deal	CNBC Television
09:20	FTC settles with Amgen over $27.8 billion takeover of Horizon Therapeutics	Market Watch
09:04	U.S. FTC allows Amgen to move forward with $27.8 bln Horizon deal - CNBC	Reuters
08:49	FTC, Amgen strike deal to allow $27.8 billion Horizon Therapeutics acquisition to move forward	CNBC
07:01	How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?	MarketBeat
Thursday, 31 August 2023
07:53	Is This the Green Light Biotech Stocks Have Been Waiting For?	The Motley Fool
Monday, 28 August 2023
23:11	FTC Attempts To Block Major Biotech Company Merger	Forbes
12:47	Horizon (HZNP) Up as FTC Pauses Acquisition by Amgen Lawsuit	Zacks Investment Research
10:50	Horizon Therapeutics Shares Surge As FTC Postpones Challenge to Merger	Investopedia
08:03	Horizon Therapeutics shares climb after FTC pauses challenge of deal with Amgen	Market Watch
Saturday, 26 August 2023
11:43	US FTC suspends challenge to block Amgen's $27.8 bln deal for Horizon Therapeutics	Reuters
Saturday, 12 August 2023
13:49	Drinks, Chips & Drugs: A Surprising List of 10-Year Stock Winners	MarketBeat
Wednesday, 9 August 2023
13:42	Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales	Zacks Investment Research
Tuesday, 8 August 2023
12:10	Compared to Estimates, Horizon Therapeutics (HZNP) Q2 Earnings: A Look at Key Metrics	Zacks Investment Research
10:40	Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates	Zacks Investment Research
Monday, 24 July 2023
12:20	Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study	Zacks Investment Research
Wednesday, 12 July 2023
15:59	Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say	Market Watch
Friday, 2 June 2023
12:40	Why Is Horizon Therapeutics (HZNP) Down 9% Since Last Earnings Report?	Zacks Investment Research
Monday, 29 May 2023
05:36	Amgen: Appeal Becomes Visible Despite Uncertainty On The 'Horizon'	Seeking Alpha

Ideas & Opinions

Seeking Alpha 14 Sep 2023

Sifting The World Day One
Seeking Alpha 16 Aug 2023

Improved Outlook For Horizon Therapeutics And Amgen
Seeking Alpha 13 Jul 2023

Viridian: Despite Drop, Advancement Towards Phase 3 Continues
Seeking Alpha 19 Jun 2023

Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half
Seeking Alpha 29 May 2023

Amgen: Appeal Becomes Visible Despite Uncertainty On The 'Horizon'
Seeking Alpha 18 May 2023

Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC
Seeking Alpha 11 Apr 2023

Viridian: A Second Buying Opportunity, But I Am Waiting For A Better Price
Seeking Alpha 28 Feb 2023

Horizon Therapeutics: Attractive 5.4% Upside To Amgen Offer
Seeking Alpha 25 Jan 2023

Why Viridian Therapeutics Is One Of My 2023 Top Picks
Seeking Alpha 11 Jan 2023

Ranking The 10 Largest Biotechs By Pipeline

Frequently Asked Questions (FAQ)

When is Horizon Therapeutics Public Limited Company's next earnings date?

Unfortunately, Horizon Therapeutics Public Limited Company's (HZNP) next earnings date is currently unknown.
Does Horizon Therapeutics Public Limited Company pay dividends?

No, Horizon Therapeutics Public Limited Company does not pay dividends.
What is Horizon Therapeutics Public Limited Company's stock symbol?

Horizon Therapeutics Public Limited Company is traded on the NASDAQ under the ticker symbol "HZNP".
What is Horizon Therapeutics Public Limited Company's primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - General industry.
How do i buy shares of Horizon Therapeutics Public Limited Company?

Shares of Horizon Therapeutics Public Limited Company can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Horizon Therapeutics Public Limited Company's key executives?
Horizon Therapeutics Public Limited Company's management team includes the following people:
- Mr. Timothy P. Walbert Chairman, Pres & Chief Executive Officer(age: 58, pay: $5,480,000)
- Mr. Paul W. Hoelscher Executive Vice President & Chief Financial Officer(age: 60, pay: $1,880,000)
- Mr. Andy Pasternak Executive Vice President & Chief Strategy Officer(age: 54, pay: $1,790,000)
- Mr. Barry J. Moze Executive Vice President & Chief Admin. Officer(age: 71, pay: $1,710,000)
- Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D. Executive Vice President & Chief Medical Officer(age: 70, pay: $1,550,000)
How many employees does Horizon Therapeutics Public Limited Company have?

As Jul 2024, Horizon Therapeutics Public Limited Company employs 2,190 workers.
When Horizon Therapeutics Public Limited Company went public?

Horizon Therapeutics Public Limited Company is publicly traded company for more then 14 years since IPO on 28 Jul 2011.
What is Horizon Therapeutics Public Limited Company's official website?

The official website for Horizon Therapeutics Public Limited Company is horizontherapeutics.com.
How can i contact Horizon Therapeutics Public Limited Company?

Horizon Therapeutics Public Limited Company can be reached via phone at +353 1 772 2100.

Horizon Therapeutics Public Limited Company

horizontherapeutics.com

Exchange:

NASDAQ

Full time employees:

2,190

Industry:

Drug Manufacturers - General

Sector:

Healthcare

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

+353 1 772 2100

70 St. Stephen’s Green
Dublin, 2

CIK: 0001492426
ISIN: IE00BQPVQZ61
CUSIP: G46188101